Venetoclax therapy for leukemia

Share This Post

On June 8 , the US FDA approved Venetoclax ( VENCLEXTA , AbbVie Inc. and Genentech Inc. ) for patients with chronic lymphocytic leukemia ( CLL ) or small lymphocytic lymphoma ( SLL ), with or without 17p deletion, at least Received a treatment.

Approval is based on MURANO ( NCT02005471 ), a randomized ( 1 : 1 ), multicenter, open-label trial comparing rituximab with venetoclax ( VEN + R ) and bendamustine with rituximab ( B + R & lt ), 389 name CLL patients received at least one previous treatment. VEN + R patients completed the protocol . 5 weeks and the amount of venetoclax treatment regimen, then the  start of rituximab, once received daily 400 mg venetoclax , a total of 24 months. Rituximab needs to be treated for 6 cycles on Venetoclax ( Intravenous injection of 375 mg / m2 on day 1 of cycle 1 , 500 mg / m2 of intravenous injection on day 1 of cycles 2-6 , one cycle 28 days). Control group . 6 cycles of B + R & lt (each 28 day cycle 1 and 2 days bendamustine 70mg / m 2 and rituximab above doses and schedules).

Assess progression-free survival ( PFS ). After a median follow-up of 23 months , the median PFS in the VEN + R group was not reached, compared with 18.1 months in the B + R group . The total response rate in the VEN + R group was 92 %, while that in the B + R group was 72 %.

Among the patients treated with VEN + R , the most common adverse reactions (incidence ≥20 %) were neutropenia, diarrhea, upper respiratory tract infection, fatigue, cough and nausea. 64 % of these patients had grade 3 or 4 neutropenia, and 31 % had grade 4 neutropenia. Serious adverse reactions occurred in 46 % of patients, severe infections occurred in 21 % of patients, the most common was pneumonia ( 9 %). Due to the rapid decrease in tumor volume, tumor lysis syndrome ( TLS ) is an important risk factor for Venetoclax treatment. Care should be taken during treatment.

https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610308.htm

 

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه
Start chat
Need help with cancer treatment?
Scan the code
Hello,
Welcome to CancerFax !

CancerFax is the most trusted international patient facilitator working with top cancer hospital's in the world like MD Anderson, Dana Farber, Asan, NCC Japan, Sheba, Beijing Cancer Institute and Apollo to bring you best of therapies and drugs.

Let us know what services would you like to avail?

1) Cancer treatment in the USA, Japan, Israel, India, Korea or Singapore?
2) CAR T-Cell therapy treatment
3) Cancer vaccine
4) Online video consultation
5) Proton therapy